Combining docking, scoring and molecular field analyses to probe influenza neuraminidase-ligand interactions

被引:22
作者
Abu Hammad, Areej M. [1 ]
Afifi, Fatma U. [1 ]
Taha, Mutasem O. [1 ]
机构
[1] Univ Jordan, Fac Pharm, Dept Pharmaceut Sci, Amman 11942, Jordan
关键词
neuraminidase inhibitors; docking; scoring; protein-aligned CoMFA; multiple binding modes;
D O I
10.1016/j.jmgm.2007.02.002
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
In this project, several docking conditions, scoring functions and corresponding protein-aligned molecular field analysis (CoMFA) models were evaluated for a diverse set of neuraminidase (NA) inhibitors. To this end, a group of inhibitors were docked into the active site of NA, The docked structures were utilized to construct a Corresponding protein-aligned CoMFA models by employing probe-based (H+, OH, CH3) energy grids and genetic partial least squares (G/PLS) statistical analysis. A total of 16 different docking configurations were evaluated, of which some succeeded in producing self-consistent and predictive CoMFA models. However, the best model coincided with docking the ionized ligands into the hydrated form of the binding site via PLP1 scoring function (r(LOO)(2) = 0.735, r(PRESS)(2) against 24 test compounds = 0.828). The highest-ranking CoMFA models were employed to probe NA-ligand interactions. Further validation by comparison with a co-crystallized ligand-NA crystallographic structure was performed. This combination of docking/scoring/CoMFA modeling provided interesting insights into the binding of different NA inhibitors. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:443 / 456
页数:14
相关论文
共 94 条
[1]
*ACC INC, 2000, CERIUS2 LIGANDFIT US, P3
[2]
*ACC INC, 2005, CERIUS2410 QSAR, P177
[3]
*ACC INC, 2003, CERIUS2 4 8 1 QSAR, P210
[4]
*ACC INC, 1997, CERIUS2 OFF, P5
[5]
*ACC SOFTW INC, 2005, CERIUS2 VERS 4 10 QS, P237
[6]
THE NEURAMINIDASE OF INFLUENZA-VIRUS [J].
AIR, GM ;
LAVER, WG .
PROTEINS-STRUCTURE FUNCTION AND GENETICS, 1989, 6 (04) :341-356
[7]
Influenza neuraminidase as target for antivirals [J].
Air, GM ;
Ghate, AA ;
Stray, SJ .
ADVANCES IN VIRUS RESEARCH, VOL 54, 1999, 54 :375-+
[8]
Optimal charges in lead progression: A structure-based neuraminidase case study [J].
Armstrong, KA ;
Tidor, B ;
Cheng, AC .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (08) :2470-2477
[9]
ARNOLD S, 2005, ENGL J MED, V352, P323
[10]
BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design [J].
Babu, YS ;
Chand, P ;
Bantia, S ;
Kotian, P ;
Dehghani, A ;
El-Kattan, Y ;
Lin, TH ;
Hutchison, TL ;
Elliott, AJ ;
Parker, CD ;
Ananth, SL ;
Horn, LL ;
Laver, GW ;
Montgomery, JA .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (19) :3482-3486